2023 World Conference on Lung Cancer (Posters)-P2.10. First-line (1L) Lorlatinib in Patients with ALK-Positive aNSCLC: Updated Network Meta-Analysis (NMA) and Review of Ten NMAs

P2.10. First-line (1L) Lorlatinib in Patients with ALK-Positive aNSCLC: Updated Network Meta-Analysis (NMA) and Review of Ten NMAs - PDF(Slides)

Back to course

Pdf Summary

This study presents an updated network meta-analysis (NMA) comparing the efficacy of lorlatinib with other tyrosine kinase inhibitors (TKIs) as first-line treatment for anaplastic lymphoma kinase-positive (ALK) advanced non-small-cell lung cancer (aNSCLC). The NMA, conducted using a Bayesian approach, confirms previous findings that lorlatinib is a clinically effective treatment for ALK aNSCLC patients compared to other ALK TKIs. The analysis includes data from 10 NMAs which consistently support the superiority of lorlatinib in terms of progression-free survival (PFS) compared to alectinib and brigatinib.<br /><br />The study also summarizes nine other independent NMAs conducted for ALK aNSCLC, comparing the study designs and results. The results from these NMAs align with the findings of the updated NMA, consistently demonstrating better PFS for lorlatinib compared to alectinib and brigatinib.<br /><br />The updated NMA used recent data from the 36-month CROWN study and ALTA-1L study, as well as additional publications for ALESIA, J-ALEX, and eXalt3. The results of the updated NMA showed minor differences compared to previous results, with no changes in statistical significance. The updated NMA confirmed that lorlatinib demonstrated significantly or numerically better PFS than other treatments.<br /><br />It is important to note some limitations of the study, including limited data for certain endpoints and the use of fixed effects models alone in the updated NMAs. Additionally, no adjustments were made for differences in study characteristics. However, the studies were previously assessed and deemed feasible for use in the NMA.<br /><br />In conclusion, the updated NMA reinforces the previous findings that lorlatinib is an effective first-line treatment for ALK aNSCLC, showing superior PFS compared to other ALK TKIs. This study adds to the existing literature on the comparative efficacy of different TKIs in ALK aNSCLC.

Asset Subtitle

Sai-Hong Ignatius Ou

Meta Tag

Speaker Sai-Hong Ignatius Ou

Topic Metastatic NSCLC: Targeted Therapy - FUSIONS

Keywords

lorlatinib

tyrosine kinase inhibitors

anaplastic lymphoma kinase-positive

non-small-cell lung cancer

network meta-analysis

progression-free survival

alectinib

brigatinib

CROWN study

ALTA-1L study